

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on March 26, 2010 has been entered.

Claims 51, 58-60, 64-68, and 70-78 are pending in the instant application.

Information Disclosure Statement

2. The IDS received March 26, 2010 is acknowledged and has been considered.
3. None of the newly cited art anticipates the instant claimed inventions, renders the instant claimed inventions obvious, or casts doubt upon the ability of an artisan to make and use the claimed inventions. Further, antibodies which bind blood factor VIII, comprise the recited sequences, and comprise the recite alterations in glycosylation are not disclosed in the prior art and are not obvious in view of the prior art. Note that the specification comprises working example exemplifying the claimed invention and thus the claimed inventions are fully enabled. Therefore, the instant claimed inventions are allowable.
4. Claims 51, 58-60, 64-68, and 70-78 are allowed.
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is (571)272-2934. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Szperka, Ph.D.
Primary Examiner
Art Unit 1644

/Michael Szperka/
Primary Examiner, Art Unit 1644